- New
LOI would allow the company to join development of a wide range of
hemp-based medicinal products
- Neutra
would also gain access to a cultivation license and a research license to
examine the role of cannabinoids as antioxidants and neuro-protectants
- CBD
sales in the U.S. expected to exceed $20 billion by 2024; hemp-based CBD
product sales reached $390 in 2018 and are expected to more than triple
over the next couple of years
Early-stage research and development company Neutra
Corp. (OTC: NTRR) executed a Letter of Intent (LOI) that could lead to
the joint development of a vast selection of additional hemp-based medicinal
products on the booming CBD market, according to a company press release (http://ibn.fm/20ek4).
Neutra intends to conclude an agreement with Orgaceutical
Co, based in Harrisburg, PA. If executed as planned, the agreement would
provide Neutra with access to Orgaceutical’s formal research findings into the
potential benefits of cannabinoids as antioxidants and neuro-protectants.
Neutra, who is expanding into hemp cultivation and purified hemp extract
products, would also gain a license for hemp cultivation issued by the
Commonwealth of Pennsylvania’s Department of Agriculture as Orgaceutical Co is
based in that state. The company would obtain rights to a federally registered
hemp trademark as well.
According to Neutra CEO Sydney Jim, this agreement would
help Neutra secure a solid position for research and development of new
applications for hem-based CBD medicinal products. “With the cultivation
license, we’ll have a constant and consistent supply of quality hemp under a
vertically integrated cultivation model. With the research license, we’ll be
free to explore new uses for hemp and products derived from it. Finally, with
the trademark, we’ll have a federally protected brand name to pair with our
existing VIVIS product line,” Jim said in a news release.
Neutra has been developing third-party certified
hemp-derived CBD health and nutritional product lines for consumers for quite
some time. The company recently acquired VIVIS, an emerging retail brand of
hemp-based health and nutritional products. VIVIS has launched a soft gel CBD
supplement, which was a crucial step in both its own and Neutra’s development
as soft gel is the most efficient CBD ingestion method. This is because an
entire dosage of CBD can be taken at once rather than spread out over time and
lost to a great extent, as it would be when consumed in a beverage or a meal.
VIVIS’ hemp-derived CBD products are third-party certified
as being of consistent quality and potency and free of contaminants. As global
CBD markets become more strictly regulated, buyers are increasingly looking for
certification when they buy these products. Neutra is expecting interest and
demand for its expanding portfolio of branded products to increase with VIVIS
as its new retail face.
Neutra recently signed a Letter of Intent to acquire J3
Holdings. This acquisition will include the latter’s land and warehouse as well
as a license to cultivate hemp and refine it into usable forms. This approach
will enable the company to grow its own hemp supply, giving it greater control
over the selection of ingredients and allowing it to make sure they are of
supreme quality.
The Orgaceutical LOI announcement came shortly after Neutra
made the news earlier in October 2019 with its new CBD-based, menthol-infused
sports cream, under the VIVIS brand (http://ibn.fm/Al8wk). With one in five Americans
participating in a sport or exercising regularly, and a growing global sports
nutrition market, the company expects considerable interest in its new product.
These recent developments give Neutra quite an advantage on
the rapidly expanding CBD product market. BDS Analytics and Arcview Market
Research project that the collective market for CBD sales in the U.S. will
exceed $20 billion by 2024, with a 49 percent compound annual growth rate
across all distribution channels (http://ibn.fm/yA3Kg). However, Neutra’s interests go above
and beyond sales. “Most of our focus, obviously, is in our quality and potency
of our products, because there is a vast difference between very cheap products
and quality product,” Jim said in an exclusive interview with NetworkNewsWire.
It takes a lot of time to extract CBD and make sure only the best quality is
made available (http://ibn.fm/O97WF).
Neutra’s vastly expanding horizons include the
commercialization of more innovative and effective products. The company is
always looking for new opportunities to accelerate its mission to bring these
products to a wider demographic. Neutra’s work reflects a strong commitment to
supporting better health, environment, and quality of life for people around
the world.
For more information, visit the company’s website at www.NeutraInc.com
NOTE TO INVESTORS: The latest news and updates
relating to NTRR are available in the company’s newsroom at http://ibn.fm/NTRR
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment